Stock ADOC ADOCIA
Add to a list
To use this feature you must be a member
Log inSign up

Adocia

Equities

ADOC

FR0011184241

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 11:35:09 2024-07-12 am EDT 		5-day change 1st Jan Change
5.44 EUR -3.72% Intraday chart for Adocia -23.27% -52.86%
Jul. 11 ADOCIA : price target reduced by Oddo BHF CF
Jul. 10 Adocia, Tonghua Dongbao End Insulin Combo License Deal MT

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Adocia

ADOCIA : price target reduced by Oddo BHF CF
Adocia, Tonghua Dongbao End Insulin Combo License Deal MT
Adocia: end of insulin partnership program CF
Adocia appoints Director of Operations CF
Adocia Announces Appointment of Mathieu-William Gilbert as Chief Operating Officer CI
Adocia SA announced that it has received funding CI
Adocia SA announced that it has received ?2 million in funding CI
Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Adocia: announces fund-raising CF
Adocia SA announced that it expects to receive ?2 million in funding CI
Adocia Reveals Promising Preclinical Data on Adocia Islets for Cell Therapy of Diabetes CI
Adocia: positive study data for BC Combo CF
Adocia SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Adocia: refinancing operations completed CF
Adocia SA announced that it has received ?9.999993 million in funding from Bpifrance Investissement SAS, Vester Finance SA CI
Adocia: exclusive right to negotiate M1Pram with Sanofi CF
Sanofi Secures EUR10 Million Exclusivity Deal for Adocia's Diabetes Drug MT
Adocia Signs an Exclusivity Agreement with Sanofi for M1Pram CI
Adocia SA announced that it expects to receive €10 million in funding CI
Adocia Requests Trading Halt on Euronext Paris MT
Adocia: listing suspended pending a press release CF
Adocia SA Auditor Raises 'Going Concern' Doubt CI
Global markets live: Deliveroo, Adobe, Berkshire Hathaway, First republic Bank, Robinhood Markets... Our Logo
Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2022 CI

Chart Adocia

Chart Adocia
More charts

Company Profile

Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. At the end of 2023, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram-ADO09 and BioChaperone Glucagon) and 3 preclinical-stage products (BioChaperone® LisPram, BioChaperone® Glargine GLP-1 and BioChaperone® Glucagon GLP-1).
Sector
Biotechnology & Medical Research
Calendar
2024-07-23 - Q2 2024 Sales and Revenue Release
More about the company

Income Statement Evolution

More financial data

Ratings for Adocia

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
5.44 EUR
Average target price
6.3 EUR
Spread / Average Target
+15.81%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ADOCIA Stock Adocia
-52.86% 89.23M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+20.12% 126B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+25.25% 119B
ARGENX SE Stock argenx SE
+25.56% 27.95B
BIONTECH SE Stock BioNTech SE
-19.51% 20.5B
GENMAB A/S Stock Genmab A/S
-14.36% 17.12B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.63% 16.1B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.67% 14.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+11.89% 14.84B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+57.74% 14.38B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ADOC Stock
  4. News Adocia
  5. Adocia Requests Trading Halt on Euronext Paris